title: Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
abstract: The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number of substituted pyrazine cores utilizing regioselective halogenation and chemoselective derivatization. Noteworthy, an efficient 5-step synthesis was developed for the lead compound 59 (NGD 98-2), which required no chromatography. Compound 59 was characterized as an orally bioavailable, brain penetrant, and highly selective CRF-1 receptor antagonist. Occupancy of rat brain CRF-1 receptors was quantified using ex vivo receptor occupancy assays, using both brain tissue homogenates as well as brain slices receptor autoradiography. Behaviorally, oral administration of 59 significantly antagonized CRF-induced locomotor activity at doses as low as 10 mg/kg and dose-dependently reduced the restraint stress-induced ACTH increases.
authors: Neurogen Corporation, 35 Northeast Industrial Road, Branford, Connecticut 06405, United States. khodgetts@galenea.com
authors: Kevin J
authors: KJ
authors: Hodgetts
authors: Ping
authors: P
authors: Ge
authors: Taeyoung
authors: T
authors: Yoon
authors: Stéphane
authors: S
authors: De Lombaert
authors: Robbin
authors: R
authors: Brodbeck
authors: Michael
authors: M
authors: Gulianello
authors: Andrzej
authors: A
authors: Kieltyka
authors: Raymond F
authors: RF
authors: Horvath
authors: John H
authors: JH
authors: Kehne
authors: James E
authors: JE
authors: Krause
authors: George D
authors: GD
authors: Maynard
authors: Diane
authors: D
authors: Hoffman
authors: Younglim
authors: Y
authors: Lee
authors: Laurence
authors: L
authors: Fung
authors: Dario
authors: D
authors: Doller